Komen Foundation 1998 Awards Honor Leaders in Fight Against Breast Cancer

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 7 No 12
Volume 7
Issue 12

DALLAS-More than 2,100 guests attended the Susan G. Komen Foundation’s 16th Annual National Awards luncheon. Candice Bergen, star of the former CBS sitcom, Murphy Brown, received the Foundation’s most prestigious honor-the Betty Ford Award-for her portrayal of the character’s battle with breast cancer during the show’s final season.

DALLAS—More than 2,100 guests attended the Susan G. Komen Foundation’s 16th Annual National Awards luncheon. Candice Bergen, star of the former CBS sitcom, Murphy Brown, received the Foundation’s most prestigious honor—the Betty Ford Award—for her portrayal of the character’s battle with breast cancer during the show’s final season.

Two breast cancer researchers were also honored. Steven E. Harms, MD, professor and director of Imaging Research, University of Arkansas, received the award for Scientific Distinction for developing a minimally invasive laser treatment for small breast cancers. [Look for a report on this research in an upcoming issue of ONI.] Gilbert F. Friedell, MD, director emeritus of the Markey Cancer Center, University of Kentucky, received the award for Individual Community Service for innovative cancer education programs and research.

Recent Videos
Whole or accelerated partial breast ultra-hypofractionated radiation in older patients with early breast cancer may reduce recurrence with low toxicity.
Ultra-hypofractionated radiation in those 65 years or older with early breast cancer yielded no ipsilateral recurrence after a 10-month follow-up.
The unclear role of hypofractionated radiation in older patients with early breast cancer in prior trials incentivized research for this group.
Patients with HR-positive, HER2-positive breast cancer and high-risk features may derive benefit from ovarian function suppression plus endocrine therapy.
Paolo Tarantino, MD discusses updated breast cancer trial findings presented at ESMO 2024 supporting the use of agents such as T-DXd and ribociclib.
Paolo Tarantino, MD, discusses the potential utility of agents such as datopotamab deruxtecan and enfortumab vedotin in patients with breast cancer.
Paolo Tarantino, MD, highlights strategies related to screening and multidisciplinary collaboration for managing ILD in patients who receive T-DXd.